Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Lila Sciences›
Products & Services
Creation

Lila Sciences› offers Creation

Product
Currently Offered

Creation uses Lila Iris and AI Science Factories to generate validated scientific assets and company opportunities.

Loading
Overview

Creation is Lila's delivery-model offering for partners that bring a problem space or thesis to the company. Lila uses Lila Iris and AI Science Factories to generate hypotheses, design and run experiments, and iteratively optimize candidates.

The offering produces validated assets such as molecular structures, materials, protocols, and data packages that partners can use in pipelines or build into new programs. For investors and strategic partners, Creation campaigns can discover novel molecules, materials, or platforms with technical differentiation, validation, intellectual property, and a de-risked roadmap.

Creation - Classification

Model
  • AI Platform

More from Lila Sciences

  • Catalyst logo

    Catalyst

Creation - Direct Competitors

  • Insilico Medicine

    Insilico Medicine logo

    Pharma.ai

    insilico.com

  • Recursion Pharmaceuticals

    Recursion Pharmaceuticals logo

    Recursion OS

    recursion.com

AttributeCreationPharma.aiRecursion OS
ProviderLila Scienceslila.ai$550M raised · Series AInsilico Medicineinsilico.com$401.3M raised · Series DRecursion Pharmaceuticalsrecursion.com$665.4M raised · Public
Founded202320142013
Sells ToEnterpriseEnterpriseEnterprise
Pricing Model—Recurring, SoftwareRecurring, Software
OwnershipVenture-backed private companyVenture CapitalPublic, Venture Capital
Creation

Provider Lila Scienceslila.ai$550M raised · Series A

Founded 2023

Sells To Enterprise

Pricing Model —

Ownership Venture-backed private company

Pharma.ai

Provider Insilico Medicineinsilico.com$401.3M raised · Series D

Founded 2014

Sells To Enterprise

Pricing Model Recurring, Software

Ownership Venture Capital

Recursion OS

Provider Recursion Pharmaceuticalsrecursion.com$665.4M raised · Public

Founded 2013

Sells To Enterprise

Pricing Model Recurring, Software

Ownership Public, Venture Capital

Creation - Similar Products & Services

  • GEMS AI Platform logo

    GEMS AI Platform

  • Drug Design Engine logo

    Drug Design Engine